Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
58 hedge funds and large institutions have $1.61B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 11 closing their positions.
4,332% more capital invested
Capital invested by funds: $36.2M → $1.61B (+$1.57B)
373% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 11
222% more funds holding
Funds holding: 18 → 58 (+40)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Bain Capital Investors
Boston,
Massachusetts
|
+$788M |
| 2 |
PA
Perceptive Advisors
New York
|
+$59M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$56M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$44.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$7.32M |
| 2 |
GL
Governors Lane
New York
|
-$6.91M |
| 3 |
SRCM
Sage Rock Capital Management
New York
|
-$3.41M |
| 4 |
CCM
Context Capital Management
Lajolla,
California
|
-$2.82M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.61M |
CERE Hedge Fund Activity: Q4 2020 in Review
58 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q4 2020, worth a combined $1.61B — up 4,332% from $36.2M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new CERE positions and 11 closed out — a net gain of 41 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Bain Capital Investors, opening a new position worth an estimated $788M. The largest seller was 683 Capital Management, exiting entirely with an estimated $7.32M sold.
- 58 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q4 2020, up from 18 in Q3 2020.
- Funds reported $1.61B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q4 2020, up 4,332% quarter-over-quarter.
- 52 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q4 2020 and 11 closed out, a net change of +41 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q4 2020 was Bain Capital Investors, an estimated $788M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q4 2020 was 683 Capital Management, an estimated $7.32M sold.
Based on aggregated 13F filings for Q4 2020.